Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Alkermes plc
Nieuws
Alkermes plc
ALKS
NAS
: ALKS
| ISIN: IE00B56GVS15
12/02/2025
33,50 USD
(+4,82%)
(+4,82%)
12/02/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
28 augustus 2024 ·
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
· Persbericht
22 augustus 2024 ·
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
· Persbericht
24 juli 2024 ·
Alkermes plc Reports Second Quarter 2024 Financial Results
· Persbericht
17 juli 2024 ·
Alkermes to Report Second Quarter Financial Results on July 24, 2024
· Persbericht
3 juni 2024 ·
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
· Persbericht
29 mei 2024 ·
Alkermes to Participate in Two Upcoming Investor Conferences
· Persbericht
28 mei 2024 ·
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
· Persbericht
14 mei 2024 ·
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
· Persbericht
2 mei 2024 ·
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
· Persbericht
1 mei 2024 ·
Alkermes plc Reports First Quarter 2024 Financial Results
· Persbericht
24 april 2024 ·
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
· Persbericht
17 april 2024 ·
Alkermes to Report First Quarter Financial Results on May 1, 2024
· Persbericht
9 april 2024 ·
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
· Persbericht
8 april 2024 ·
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
· Persbericht
7 maart 2024 ·
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
· Persbericht
15 februari 2024 ·
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
· Persbericht
8 februari 2024 ·
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
· Persbericht
3 januari 2024 ·
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
· Persbericht
3 januari 2024 ·
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
· Persbericht
14 december 2023 ·
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe